Channel Therapeutics Stock Soars 78.49% on Merger, FDA Approval

Channel Therapeutics Corporation's stock surged 78.49% in pre-market trading on April 18, 2025, driven by a series of significant developments that have captured investor attention.

Channel Therapeutics Corporation's stock has seen a remarkable surge, driven by the announcement of a definitive merger agreement with Ligand Pharmaceuticals. This merger involves Ligand's Pelthos Therapeutics and LNHC subsidiaries, which has sparked significant investor optimism and fueled the stock's upward trajectory.

Additionally, the company's stock soared following the release of promising study results and FDA approval, further bolstering investor confidence. These developments have positioned Channel Therapeutics as a company to watch in the biotech sector, with investors eagerly anticipating further advancements and potential partnerships.